LENZ THERAPEUTICS ($LENZ) posted quarterly earnings results for Q4 2025 on Tuesday, March 24th. The company reported earnings of -$1.16 per share, missing estimates of -$0.99 by $0.17. The company also reported revenue of $1,590,000, missing estimates of $1,923,893 by $-333,893.
You can see Quiver Quantitative's $LENZ stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
LENZ THERAPEUTICS Insider Trading Activity
LENZ THERAPEUTICS insiders have traded $LENZ stock on the open market 11 times in the past 6 months. Of those trades, 3 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $LENZ stock by insiders over the last 6 months:
- VENTURE CAPITAL VI, L.P. VERSANT has made 0 purchases and 6 sales selling 224,974 shares for an estimated $10,352,017.
- SHAWN OLSSON (Chief Commercial Officer) has made 0 purchases and 2 sales selling 10,000 shares for an estimated $261,022.
- JAMES W MCCOLLUM purchased 10,500 shares for an estimated $239,278
- DANIEL R. CHEVALLARD (Chief Financial Officer) has made 2 purchases buying 2,198 shares for an estimated $50,016 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
LENZ THERAPEUTICS Hedge Fund Activity
We have seen 97 institutional investors add shares of LENZ THERAPEUTICS stock to their portfolio, and 89 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 3,615,405 shares (+4140.7%) to their portfolio in Q4 2025, for an estimated $57,846,480
- PARADIGM BIOCAPITAL ADVISORS LP removed 1,073,461 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $17,175,376
- RTW INVESTMENTS, LP removed 863,389 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $13,814,224
- PRICE T ROWE ASSOCIATES INC /MD/ added 772,411 shares (+307.6%) to their portfolio in Q4 2025, for an estimated $12,358,576
- FIRST LIGHT ASSET MANAGEMENT, LLC removed 693,044 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $11,088,704
- INTRINSIC EDGE CAPITAL MANAGEMENT LLC added 569,705 shares (+inf%) to their portfolio in Q4 2025, for an estimated $9,115,280
- MILLENNIUM MANAGEMENT LLC added 539,348 shares (+inf%) to their portfolio in Q4 2025, for an estimated $8,629,568
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
LENZ THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $LENZ in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 10/10/2025
To track analyst ratings and price targets for LENZ THERAPEUTICS, check out Quiver Quantitative's $LENZ forecast page.
LENZ THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $LENZ recently. We have seen 2 analysts offer price targets for $LENZ in the last 6 months, with a median target of $58.5.
Here are some recent targets:
- Gary Nachman from Raymond James set a target price of $50.0 on 10/20/2025
- Biren Amin from Piper Sandler set a target price of $67.0 on 10/10/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
